KalVista Pharmaceuticals
KALV
KALV was delisted on the 10th of June, 2026.
72 hedge funds and large institutions have $194M invested in KalVista Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 14 funds opening new positions, 24 increasing their positions, 18 reducing their positions, and 11 closing their positions.
59% more capital invested
Capital invested by funds: $122M → $194M (+$71.8M)
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
33% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 18
27% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 11
4% more funds holding
Funds holding: 69 → 72 (+3)
0.34% more ownership
Funds ownership: 89.23% → 89.56% (+0.34%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$5.99M |
| 2 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$2.51M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
+$2.07M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.77M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Victory Capital Management
San Antonio,
Texas
|
-$4.64M |
| 2 |
PC
Polar Capital
London,
United Kingdom
|
-$4.5M |
| 3 |
O
OrbiMed
New York
|
-$3.22M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$715K |
| 5 |
Squarepoint
New York
|
-$649K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
76
Bridgeway Capital Management
Houston,
Texas
| – | -$462K | -60,400 | Closed |
|
77
Marshall Wace
London,
United Kingdom
| – | -$141K | -18,454 | Closed |
|
|
GCP
78
GSA Capital Partners
London,
United Kingdom
| – | -$128K | -16,786 | Closed |
|
|
SIM
79
Spark Investment Management
New York
| – | -$98K | -12,910 | Closed |
|
80
Invesco
Atlanta,
Georgia
| – | -$83K | -10,884 | Closed |
|
|
NFG
81
Next Financial Group
Houston,
Texas
| – | -$36K | -4,683 | Closed |
|
82
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$2K | -266 | Closed |
|
KALV Hedge Fund Activity: Q2 2020 in Review
72 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q2 2020, worth a combined $194M — up 59% from $122M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new KALV positions and 11 closed out — a net gain of 3 holders — while 24 added to existing stakes and 18 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $5.99M. The largest seller was Victory Capital Management, cutting an estimated $4.64M.
- 72 institutional investors held KalVista Pharmaceuticals (KALV) as of Q2 2020, up from 69 in Q1 2020.
- Funds reported $194M of KalVista Pharmaceuticals stock for Q2 2020, up 59% quarter-over-quarter.
- 14 funds opened new KalVista Pharmaceuticals positions in Q2 2020 and 11 closed out, a net change of +3 holders.
- The largest KalVista Pharmaceuticals buyer in Q2 2020 was Logos Global Management, an estimated $5.99M added.
- The largest KalVista Pharmaceuticals seller in Q2 2020 was Victory Capital Management, an estimated $4.64M sold.
Based on aggregated 13F filings for Q2 2020.